Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence

Venkatesan Thiruvenkatarajan, Joshua M. Inglis, Emily Meyer, Mahesh M. Umapathysivam, Nagesh Nanjappa, Roelof Van Wijk, David Jesudason

Research output: Contribution to journalReview articlepeer-review

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes. With increased use, there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. In this work, we outline the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and Australian Diabetes Society guidelines.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalCanadian Journal of Diabetes
Volume47
Issue number3
Early online date24 Dec 2022
DOIs
Publication statusPublished - Apr 2023

Keywords

  • colonoscopy
  • diabetes
  • ketoacidosis
  • peri-colonoscopy
  • review
  • SGLT2i

Fingerprint

Dive into the research topics of 'Peri-colonoscopy Implications of Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Mini-review of Available Evidence'. Together they form a unique fingerprint.

Cite this